… This phase II study of erlotinib in patients with HER1/EGFR-expressing non–small-cell lung
cancer previously treated with platinum-based chemotherapy evaluated tumor response, …

… to determine whether the epidermal growth factor receptor inhibitor erlotinib prolongs
survival in non–small-cell lung cancer after the failure of first-line or second-line chemotherapy. …

… benefit from erlotinib. To clarify the role of EGFR in the outcome of non–small-cell lung cancer,
we … of EGFR, and mutation status of the gene in a subgroup of patients in the BR.21 study. …

… Although treatment with cytotoxic agents has produced modest survival improvement in
patients with stage III and IV non-small cell lung cancer (NSCLC), it appears that a plateau has …

… (EGFR) –targeted drugs in patients with non–small-cell lung cancer (NSCLC). We investigated
whether dual inhibition of MET/EGFR results in clinical benefit in patients with NSCLC. …

… of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by erlotinib. However,
there … of gefitinib and erlotinib are directly compared. Thus, we aimed to compare them. …

… on 4068 concentration samples from 1047 patients receiving erlotinib as a single agent or in
… erlotinib exposure in non-small cell lung cancer patients treated with single-agent erlotinib. …

… Symptom improvement in lung cancer patients treated with erlotinib: quality of life
analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. …

… or placebo with gemcitabine and carboplatin or cisplatin followed by maintained erlotinib
or placebo in patients with stage IIIB/IV non-small-cell lung cancer. The study was undertaken …

… Sunitinib plus erlotinib may enhance antitumor activity compared with either agent alone …
cell lung cancer (NSCLC), based on the importance of the signaling pathways involved in tumor …